[go: up one dir, main page]

BR9812096A - Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos - Google Patents

Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos

Info

Publication number
BR9812096A
BR9812096A BR9812096-4A BR9812096A BR9812096A BR 9812096 A BR9812096 A BR 9812096A BR 9812096 A BR9812096 A BR 9812096A BR 9812096 A BR9812096 A BR 9812096A
Authority
BR
Brazil
Prior art keywords
analogues
soluble receptor
ligand protein
interleukin
receptor
Prior art date
Application number
BR9812096-4A
Other languages
English (en)
Other versions
BR9812096B1 (pt
Inventor
Michael Revel
Judith Chebath
Tsvee Lapidot
Orit Kollet
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR9812096A publication Critical patent/BR9812096A/pt
Publication of BR9812096B1 publication Critical patent/BR9812096B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Patente de Invenção: <B>"PROTEìNA RECEPTORA/LIGANTE SOLúVEL INTERLEUCINA-6 QUIMéRICA, SEUS ANáLOGOS E SEUS USOS"<D>. Proteínas quiméricas construídas a partir da fusão da forma ocorrendo naturalmente do receptor IL-6 solúvel e IL-6 que são úteis para tratamento de câncer e distúrbios de fígado, aperfeiçoamento de transplante de medula óssea, e tratamento de outras condições relacionadas com IL-6 são providos.
BRPI9812096-4A 1997-07-10 1998-07-09 proteìna interleucina-6 (il-6) receptor de interleucina-6 (sil-6r) solúvel glicosilada quimérica (sil-6r/il-6) e seus análogos biologicamente ativos, seu processo para preparação e uso, bem como seqüência de dna, vetor de dna e composição farmacêutica. BR9812096B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL121284 1997-07-10
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL122818 1997-12-30
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
BR9812096A true BR9812096A (pt) 2000-07-18
BR9812096B1 BR9812096B1 (pt) 2011-09-06

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9812096-4A BR9812096B1 (pt) 1997-07-10 1998-07-09 proteìna interleucina-6 (il-6) receptor de interleucina-6 (sil-6r) solúvel glicosilada quimérica (sil-6r/il-6) e seus análogos biologicamente ativos, seu processo para preparação e uso, bem como seqüência de dna, vetor de dna e composição farmacêutica.

Country Status (26)

Country Link
US (2) US7198781B1 (pt)
EP (1) EP0991661B1 (pt)
JP (1) JP4402288B2 (pt)
KR (1) KR100505172B1 (pt)
CN (1) CN1185348C (pt)
AR (1) AR013201A1 (pt)
AT (1) ATE342915T1 (pt)
AU (1) AU758161B2 (pt)
BG (1) BG64680B1 (pt)
BR (1) BR9812096B1 (pt)
CA (1) CA2295936C (pt)
CY (1) CY1105895T1 (pt)
CZ (1) CZ302488B6 (pt)
DE (1) DE69836217T2 (pt)
DK (1) DK0991661T3 (pt)
EA (1) EA004793B1 (pt)
EE (1) EE05519B1 (pt)
ES (1) ES2271999T3 (pt)
HU (1) HU225855B1 (pt)
IL (2) IL122818A0 (pt)
NO (1) NO327397B1 (pt)
NZ (1) NZ502139A (pt)
PL (1) PL199212B1 (pt)
PT (1) PT991661E (pt)
SK (1) SK287039B6 (pt)
WO (1) WO1999002552A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
RU2346951C2 (ru) * 1999-03-09 2009-02-20 Займодженетикс, Инк. Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты)
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
US20040057928A1 (en) * 2000-09-14 2004-03-25 Nicole Deglon Use of il-6r/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1499332A4 (en) * 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP3354723B1 (en) 2005-08-29 2023-12-13 Technion Research & Development Foundation Ltd. Media for culturing stem cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
EP2059586B1 (en) 2006-08-02 2016-07-20 Technion Research & Development Foundation Ltd. Methods of expanding embryonic stem cells in a suspension culture
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
EP2171071B1 (en) * 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
JP2010535487A (ja) * 2007-08-03 2010-11-25 アステリオン・リミテッド 顆粒球コロニー刺激因子
AU2009266873A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
CA2729747A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Il6 immunotherapeutics
WO2010081738A1 (en) 2009-01-16 2010-07-22 Agirx Limited Vaccine compositions
DK3633025T3 (da) 2009-11-12 2022-12-12 Technion Res & Dev Foundation Dyrkningsmedier, cellekulturer og metoder til dyrkning af pluripotente stamceller i en udifferentieret tilstand
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CA3150342A1 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Limited Novel methods and culture media for culturing pluripotent stem cells
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
US20160194369A1 (en) * 2013-08-12 2016-07-07 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of inerest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6
CN116064563B (zh) * 2022-11-04 2025-11-11 广州达安基因股份有限公司 白细胞介素-6截短体的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
ES2174530T3 (es) * 1997-12-19 2002-11-01 Applied Research Systems Complejo ifnar/ifn.

Also Published As

Publication number Publication date
JP2001509371A (ja) 2001-07-24
CY1105895T1 (el) 2011-02-02
CA2295936A1 (en) 1999-01-21
KR100505172B1 (ko) 2005-08-03
PL338002A1 (en) 2000-09-25
EP0991661A2 (en) 2000-04-12
AU758161B2 (en) 2003-03-20
BR9812096B1 (pt) 2011-09-06
EA200000109A1 (ru) 2000-08-28
KR20010021522A (ko) 2001-03-15
EA004793B1 (ru) 2004-08-26
NO20000086L (no) 2000-03-08
HK1031895A1 (en) 2001-06-29
NO327397B1 (no) 2009-06-22
BG64680B1 (bg) 2005-11-30
DE69836217T2 (de) 2007-08-23
EE05519B1 (et) 2012-02-15
AU8127198A (en) 1999-02-08
DE69836217D1 (de) 2006-11-30
CN1269835A (zh) 2000-10-11
CZ200075A3 (cs) 2000-08-16
EE200000012A (et) 2000-08-15
IL122818A0 (en) 1998-08-16
HUP0002426A2 (hu) 2000-11-28
IL133972A (en) 2015-07-30
NZ502139A (en) 2002-03-28
WO1999002552A3 (en) 1999-04-01
PT991661E (pt) 2007-01-31
WO1999002552A2 (en) 1999-01-21
JP4402288B2 (ja) 2010-01-20
SK287039B6 (sk) 2009-10-07
EP0991661B1 (en) 2006-10-18
HUP0002426A3 (en) 2003-01-28
US20070172455A1 (en) 2007-07-26
ES2271999T3 (es) 2007-04-16
PL199212B1 (pl) 2008-08-29
CN1185348C (zh) 2005-01-19
NO20000086D0 (no) 2000-01-07
CA2295936C (en) 2009-05-26
DK0991661T3 (da) 2007-02-05
ATE342915T1 (de) 2006-11-15
SK62000A3 (en) 2000-07-11
AR013201A1 (es) 2000-12-13
HU225855B1 (en) 2007-11-28
CZ302488B6 (cs) 2011-06-15
US7374912B2 (en) 2008-05-20
BG104070A (en) 2000-11-30
US7198781B1 (en) 2007-04-03

Similar Documents

Publication Publication Date Title
BR9812096A (pt) Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos
NO990985D0 (no) Katalytisk blanding egnet for Fischer-Tropsch-prosessen
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
PL346443A1 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
EP2105449A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
EP0911321A3 (en) Compounds for the treatment of osteoporosis
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
ZA988585B (en) Pharmaceutical compositions containing plasma protein.
EP1011704A4 (en) ANALOGS OF PEPTIDES DERIVED FROM TUMOR NECROSIS FACTOR RECEPTORS
WO1998058911A3 (en) Prostaglandin agonists
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
PT1089968E (pt) Analogos de hormona tiroideia e metodos para a sua preparacao
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
IL145689A0 (en) Methods
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
EP1304123A3 (en) Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DK0923599T3 (da) Fremgangsmåde til fremstilling af 17-estere af 9alfa, 21-dihalogenpregnan-11beta, 17alfa-diol-20-oner
WO1997003701A3 (en) Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
IT1295934B1 (it) Procedimento migliorato per la sintesi di alchilpoliglucosidi
DE69811677D1 (de) Verfahren zur präparation von enantiomer-angereicherten, n-derivatisierten laktamen.
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/09/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)